Genome Biologics identifies viable drug candidates and FDA approved drug repositioning compounds for Cardiovascular and Cardiometabolic disease. Capitalising on the power of our patented Artificial Intelligence (AI) driven preclinical multi-modality drug testing technology - We leverage the power of AI-based machine learning with transformative single cell in vitro and in vivo transgenesis to dramatically reduce the cost, time, and ethical burden of preclinical research in the pharmaceutical industry.

Specialties
Drug Development, Transgenesis, AI-driven Drug-Disease Associations, Drug Repurposing, High-throughput in vivo drug validation, and Patient-optimised Drug Identification and Analytics